These results suggest the numbers of Gcg+ and Sst+ cells are not altered by senolytic treatment and that Gcg+/SstLow cells are not a consequence of senescent β cell accumulation during T1D progression in vivo. The gene discussed is GCG; the disease is type 1 diabetes mellitus.